AI
CPRX

Atria Investments’s Catalyst Pharmaceutical CPRX Stock Holding History

Atria Investments’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$277K Buy
8,824
+406
+5% +$12K ﹤0.01% 1906
2026
Q1 		$208K Buy
+8,418
New +$201K ﹤0.01% 1959

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Atria Investments's CPRX Position: Q2 2026 in Review

Atria Investments increased its Catalyst Pharmaceutical (CPRX) stake by 4.8% in Q2 2026, buying an estimated $12K and bringing the position to 8,824 shares worth $277K. The position accounts for ﹤0.01% of the portfolio, ranked #1906.

Atria Investments first reported a position in CPRX in Q1 2026 and has held it in 2 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Atria Investments held 8,824 shares of Catalyst Pharmaceutical worth $277K as of Q2 2026.
  • Atria Investments bought 406 Catalyst Pharmaceutical shares in Q2 2026, an estimated $12K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Atria Investments's portfolio in Q2 2026, its #1906 holding.
  • Atria Investments first reported a position in Catalyst Pharmaceutical in Q1 2026 and has held it in 2 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Atria Investments's 13F filing for Q2 2026, filed 28 Jul 2026.